JP2014530249A - ネツピタントおよびパロノセトロンの治療学的組合せ - Google Patents

ネツピタントおよびパロノセトロンの治療学的組合せ Download PDF

Info

Publication number
JP2014530249A
JP2014530249A JP2014536344A JP2014536344A JP2014530249A JP 2014530249 A JP2014530249 A JP 2014530249A JP 2014536344 A JP2014536344 A JP 2014536344A JP 2014536344 A JP2014536344 A JP 2014536344A JP 2014530249 A JP2014530249 A JP 2014530249A
Authority
JP
Japan
Prior art keywords
ibs
pharmaceutically acceptable
acceptable salt
palonosetron
netupitant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014536344A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530249A5 (Direct
Inventor
ピエトラ，クラウディオ
カントレッジ，セルジオ
Original Assignee
ヘルシン ヘルスケア ソシエテ アノニム
ヘルシン ヘルスケア ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヘルシン ヘルスケア ソシエテ アノニム, ヘルシン ヘルスケア ソシエテ アノニム filed Critical ヘルシン ヘルスケア ソシエテ アノニム
Publication of JP2014530249A publication Critical patent/JP2014530249A/ja
Publication of JP2014530249A5 publication Critical patent/JP2014530249A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014536344A 2011-10-18 2012-10-10 ネツピタントおよびパロノセトロンの治療学的組合せ Pending JP2014530249A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161548514P 2011-10-18 2011-10-18
US61/548,514 2011-10-18

Publications (2)

Publication Number Publication Date
JP2014530249A true JP2014530249A (ja) 2014-11-17
JP2014530249A5 JP2014530249A5 (Direct) 2015-11-19

Family

ID=47178220

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014536344A Pending JP2014530249A (ja) 2011-10-18 2012-10-10 ネツピタントおよびパロノセトロンの治療学的組合せ

Country Status (11)

Country Link
US (1) US9358228B2 (Direct)
EP (2) EP2744497B1 (Direct)
JP (1) JP2014530249A (Direct)
CN (3) CN103889423B (Direct)
DK (1) DK2744497T3 (Direct)
ES (1) ES2579616T3 (Direct)
HK (1) HK1198121A1 (Direct)
HU (1) HUE030811T2 (Direct)
PL (1) PL2744497T3 (Direct)
PT (1) PT2744497T (Direct)
WO (1) WO2013057554A2 (Direct)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3435980T (pt) * 2016-06-06 2020-02-21 Helsinn Healthcare Sa Formulações injetáveis fisiologicamente equilibradas de fosnetupitant
CN108721214B (zh) * 2017-04-14 2020-06-16 和龙 奈妥吡坦和帕洛诺司琼复方纳米粒溶液、纳米粒及制备方法和用途
TW202428273A (zh) 2023-01-03 2024-07-16 瑞士商赫爾辛保健公司 奈妥吡坦(netupitant)及帕洛諾司瓊(palonosetron)的液態口服調配物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001518495A (ja) * 1997-10-07 2001-10-16 グラクソ グループ リミテッド 薬 剤
JP2002537245A (ja) * 1999-02-18 2002-11-05 ノバルティス アクチエンゲゼルシャフト ５−ｈｔ３レセプターアンタゴニストの使用
JP2006516976A (ja) * 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 機能性腸障害を処置する方法
JP2009535364A (ja) * 2006-05-03 2009-10-01 シーエヌエスバイオ ピーティーワイ リミテッド 炎症性疼痛の治療のための方法および組成物
WO2011061622A1 (en) * 2009-11-18 2011-05-26 Helsinn Healthcare S.A. Compositions for treating centrally mediated nausea and vomiting

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236225A (en) 1989-11-28 1992-09-25 Syntex Inc Azabicyclic-substituted isoquinoline derivatives, intermediates and pharmaceutical compositions
US5510486A (en) 1994-07-26 1996-04-23 Syntex (U.S.A.) Inc. Process for preparing 2-(1-azabicyclo 2.2.2!oct-3-yl)-2,3,3A,4,5,6-hexahydro-1H-benz de!isoquinolin-1-one
DK1394150T3 (da) 1999-02-24 2011-03-21 Hoffmann La Roche 4-phenylpyridinderivater og deres anvendelse som NK-1-receptorantagonister
CN1178917C (zh) 2000-07-14 2004-12-08 弗·哈夫曼-拉罗切有限公司 作为nk1受体拮抗剂前药的4-苯基-吡啶衍生物的n-氧化物
AU2002216085B8 (en) 2000-12-14 2006-03-02 F. Hoffmann-La Roche Ag Self Emulsifying Lipid Matrix (SELM)
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
JO2676B1 (en) * 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
MY142804A (en) 2004-07-01 2011-01-14 Opko Health Inc Nk1 antagonists
CA2666512C (en) 2006-10-24 2014-05-27 Helsinn Healthcare S.A. Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability
US20100316678A1 (en) 2007-06-28 2010-12-16 Cnsbio Pty Ltd. Combination methods and compositions for treatment of neuropathic pain

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001518495A (ja) * 1997-10-07 2001-10-16 グラクソ グループ リミテッド 薬 剤
JP2002537245A (ja) * 1999-02-18 2002-11-05 ノバルティス アクチエンゲゼルシャフト ５−ｈｔ３レセプターアンタゴニストの使用
JP2006516976A (ja) * 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 機能性腸障害を処置する方法
JP2009535364A (ja) * 2006-05-03 2009-10-01 シーエヌエスバイオ ピーティーワイ リミテッド 炎症性疼痛の治療のための方法および組成物
WO2011061622A1 (en) * 2009-11-18 2011-05-26 Helsinn Healthcare S.A. Compositions for treating centrally mediated nausea and vomiting

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY, vol. 19, JPN6016026710, February 2011 (2011-02-01), pages 2242 - 2251, ISSN: 0003357975 *

Also Published As

Publication number Publication date
DK2744497T3 (en) 2016-08-01
PL2744497T3 (pl) 2016-10-31
HK1198121A1 (en) 2015-03-13
EP2744497B1 (en) 2016-04-06
CN103889423A (zh) 2014-06-25
HK1194977A1 (zh) 2014-10-31
CN105412110A (zh) 2016-03-23
HUE030811T2 (hu) 2017-05-29
CN106974912A (zh) 2017-07-25
CN105412110B (zh) 2018-05-25
EP2744497A2 (en) 2014-06-25
EP2759298A1 (en) 2014-07-30
PT2744497T (pt) 2016-07-18
US9358228B2 (en) 2016-06-07
EP2759298B1 (en) 2018-01-17
WO2013057554A3 (en) 2013-07-11
ES2579616T3 (es) 2016-08-12
WO2013057554A2 (en) 2013-04-25
CN103889423B (zh) 2016-10-19
US20140256737A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
Sang et al. AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans
Gonzalez-Rothi et al. Intermittent hypoxia and neurorehabilitation
TW201249425A (en) Cannabinoids for use in the treatment of neuropathic pain
JP2017510607A5 (Direct)
Mickle et al. Antinociceptive effects of melatonin in a rat model of post-inflammatory visceral hyperalgesia: a centrally mediated process
Lim et al. Improvement of" bouncy gait" in Lance-Adams syndrome with perampanel
CN106389740A (zh) 一种预防和/或延缓老年轻度认知障碍的组合物及其使用方法
CN103889423B (zh) 奈妥匹坦和帕洛诺司琼的治疗性组合
Fox et al. 14 Rehabilitating the Painful Patient: Pain Management in Physical Rehabilitation
EP3031455B1 (en) Agent for the treatment and prevention of sleep disorders
Wiese et al. Effects of acetylcholinesterase inhibition on quality of recovery from isoflurane-induced anesthesia in horses
Kitzman et al. Gabapentin suppresses spasticity in the spinal cord–injured rat
Evans et al. Nifuratel compared with metronidazole in the treatment of trichomonal vaginitis
CN102781437A (zh) 阿戈美拉汀在得到预定治疗强迫性障碍(ocd)的药物中的用途
KR102374820B1 (ko) 프레가발린 및 티아넵틴을 포함하는 신경병성 통증 치료용 약학적 조성물
JP2014530249A5 (Direct)
Kim et al. The effect of transcutaneous electrical nerve stimulation on pain during venous cannulation
MXPA06006685A (es) Uso de gaboxadol para tratar el insomnio.
TWI533869B (zh) 蒽醌［２，１－ｃ］［１，２，５］噻二唑－６，１１－二酮化合物緩解疼痛的應用
CN114788821A (zh) 一种药物组合物及其用途
MM Clinical evaluation of epidural bupivacaine, butorphanol, and butorphanol-bupivacaine combination in goat
HK1194977B (en) Therapeutic combinations of netupitant and palonosetron
TWI533871B (zh) 萘并［２，３－ｆ］喹喔啉－７，１２－二酮化合物緩解疼痛的應用
Tropea et al. Treating Rett Syndrome: Current Approaches and New Treatments
Rebhun Clinical observations on iproniazid in idiots with epilepsy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170321

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180206